Designing Glioblastoma-based Targeted Therapy using Permeable Macromolecules: A Concise Note

Abstract

Glioblastoma multiforme (GBM) remains one of the most aggressive and treatment-resistant forms of brain cancer, with a notoriously poor prognosis. A major hurdle in effectively targeting GBM is the presence of the blood-brain barrier (BBB), a highly selective barrier that impedes the delivery of therapeutic agents to the tumor site. This review examines the potential of permeable macromolecules as a novel approach for targeted therapy in GBM treatment. We explore the design and function of these macromolecules, which are engineered to traverse the BBB and deliver therapeutic agents directly to the tumor, thereby enhancing treatment efficacy and minimizing systemic toxicity. The review highlights various types of permeable macromolecules, including their mechanisms of BBB penetration, and the strategies employed to optimize their therapeutic payload. We also address the challenges in the development and clinical translation of these macromolecules, including issues related to biocompatibility, pharmacokinetics, and targeted delivery. Additionally, we discuss the potential of these macromolecules in overcoming drug resistance and preventing tumor recurrence, key concerns in GBM treatment. This review underscores the promising future of permeable macromolecules in GBM therapy, offering insights into their role in advancing personalized and targeted treatment strategies. With continued research and development, these macromolecules hold the potential to significantly improve outcomes for patients suffering from this devastating disease.

Keywords:

• blood brain barrier
• excipient
• glioblastoma
• macromolecule
• penetration

Disclosure statement

No potential conflict of interest was reported by the author(s).